L3VLUP
ProSign in

AGIO · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

AGIOLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • AGIO
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterAGIOLLY
Q3 20209 holders, $371m33 holders, $14.1bn
Q4 20209 holders, $441m29 holders, $17.3bn
Q1 20219 holders, $483m24 holders, $23.0bn
Q2 20216 holders, $892m24 holders, $27.8bn
Q3 20216 holders, $283m31 holders, $29.9bn
Q4 20215 holders, $220m31 holders, $34.7bn
Q1 20227 holders, $203m24 holders, $35.3bn
Q2 20225 holders, $40m33 holders, $42.7bn
Q3 20227 holders, $198m31 holders, $43.4bn
Q4 20226 holders, $218m31 holders, $46.6bn
Q1 20235 holders, $186m33 holders, $44.3bn
Q2 20234 holders, $251m37 holders, $59.6bn
Q3 20234 holders, $205m44 holders, $67.6bn
Q4 20233 holders, $106m45 holders, $73.6bn
Q1 20245 holders, $180m41 holders, $95.3bn
Q2 202410 holders, $358m43 holders, $110bn
Q3 20246 holders, $332m45 holders, $107bn
Q4 20244 holders, $206m46 holders, $93.9bn
Q1 20253 holders, $181m42 holders, $98.4bn
Q2 20254 holders, $215m43 holders, $93.2bn
Q3 20253 holders, $250m39 holders, $86.7bn
Q4 20254 holders, $159m41 holders, $123bn
Q1 20265 holders, $306m39 holders, $106bn
Q2 20264 holders, $354m44 holders, $132bn
AGIO

Agios Pharmaceuticals Inc

Holders
10
Reported value
$358m
Buyers
8
Sellers
2

Breadth +6 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
43
Reported value
$110bn
Buyers
29
Sellers
17

Breadth +12 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2024

Among the 46 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only AGIO (3)

Farallon Capital Management LLC, PDT Partners LLC, Voloridge Investment Management LLC

Only LLY (36)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, ExodusPoint Capital Management LP, Fidelity (FMR LLC), GAMCO Investors Inc, Holocene Advisors LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Polen Capital Management LLC, Quantbot Technologies LP, and 11 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →